Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Treosulfan (Primary) ; Allogeneic stem cell therapy; Antithymocyte globulin; Fludarabine; Mycophenolate mofetil; Rituximab; Sirolimus
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms TrRaMM4Gy

12 Dec 2018 Status changed from recruiting to completed.
10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
08 Jun 2012 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com